Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Clinical-Grade Human Pluripotent Stem Cells for Cell Therapy: Characterization Strategy

D. Rehakova, T. Souralova, I. Koutna

. 2020 ; 21 (7) : . [pub] 20200331

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012773

Grantová podpora
CZ.02.1.01/0.0/0.0/16_019/0000868 European Regional Development Fund
CZ.02.1.01/0.0/0.0/15_003/0000492 European Regional Development Fund
NV18-08-00412 Ministerstvo Zdravotnictví Ceské Republiky

Human pluripotent stem cells have the potential to change the way in which human diseases are cured. Clinical-grade human embryonic stem cells and human induced pluripotent stem cells have to be created according to current good manufacturing practices and regulations. Quality and safety must be of the highest importance when humans' lives are at stake. With the rising number of clinical trials, there is a need for a consensus on hPSCs characterization. Here, we summarize mandatory and 'for information only' characterization methods with release criteria for the establishment of clinical-grade hPSC lines.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012773
003      
CZ-PrNML
005      
20210714100002.0
007      
ta
008      
210420s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms21072435 $2 doi
035    __
$a (PubMed)32244538
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Rehakova, Daniela $u Department of Experimental Biology, Faculty of Science, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic ; International Clinical Research Center, St. Anne's University Hospital Brno, Pekařská 53, 656 91 Brno, Czech Republic
245    10
$a Clinical-Grade Human Pluripotent Stem Cells for Cell Therapy: Characterization Strategy / $c D. Rehakova, T. Souralova, I. Koutna
520    9_
$a Human pluripotent stem cells have the potential to change the way in which human diseases are cured. Clinical-grade human embryonic stem cells and human induced pluripotent stem cells have to be created according to current good manufacturing practices and regulations. Quality and safety must be of the highest importance when humans' lives are at stake. With the rising number of clinical trials, there is a need for a consensus on hPSCs characterization. Here, we summarize mandatory and 'for information only' characterization methods with release criteria for the establishment of clinical-grade hPSC lines.
650    _2
$a Bacteria $7 D001419
650    _2
$a buněčná a tkáňová terapie $x metody $7 D064987
650    _2
$a endotoxiny $7 D004731
650    _2
$a lidské embryonální kmenové buňky $7 D000066449
650    _2
$a lidé $7 D006801
650    _2
$a indukované pluripotentní kmenové buňky $7 D057026
650    _2
$a Mycoplasma $7 D009174
650    12
$a pluripotentní kmenové buňky $7 D039904
650    _2
$a viry $7 D014780
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Souralová, Tereza $u International Clinical Research Center, St. Anne's University Hospital Brno, Pekařská 53, 656 91 Brno, Czech Republic ; Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Kamenice 3, 625 00 Brno, Czech Republic $7 xx0260467
700    1_
$a Koutna, Irena $u International Clinical Research Center, St. Anne's University Hospital Brno, Pekařská 53, 656 91 Brno, Czech Republic ; Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Kamenice 3, 625 00 Brno, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 21, č. 7 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32244538 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210714100000 $b ABA008
999    __
$a ok $b bmc $g 1651020 $s 1133152
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 21 $c 7 $e 20200331 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a CZ.02.1.01/0.0/0.0/16_019/0000868 $p European Regional Development Fund
GRA    __
$a CZ.02.1.01/0.0/0.0/15_003/0000492 $p European Regional Development Fund
GRA    __
$a NV18-08-00412 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20210420
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace